Emergency Biomarkers for Early Clinical Deterioration: Evidence-Based Review for Rapid Risk Stratification

Abstract

Early identification of clinical deterioration remains a cornerstone of emergency and critical care, yet timely recognition is often hindered by non-specific presentations and the limitations of conventional monitoring. This review synthesizes recent evidence on emergency biomarkers that enable rapid detection of physiological decline, facilitating prompt intervention and improved patient outcomes. Emphasis is placed on the mechanistic basis, diagnostic accuracy, and clinical utility of established and emerging biomarkers in the acute care setting, with practical recommendations for integration into current practice pathways.

Introduction

Clinical deterioration in the emergency department (ED) and acute care settings is associated with increased morbidity, mortality, and healthcare utilization. Despite technological advancements, early recognition continues to challenge clinicians due to overlapping symptoms, subjective assessments, and limited predictive value of routine vital signs. The advent of emergency biomarkers a spectrum of measurable molecular indicators reflecting underlying pathophysiological processes offers a promising solution for risk stratification, prognostication, and tailored interventions. This review aims to provide an evidence-based synthesis of key emergency biomarkers, their pathophysiological underpinnings, diagnostic performance, and implications for acute care management.

Epidemiology / Disease Burden

Globally, millions of patients present to EDs annually with acute illness at risk of rapid deterioration, including sepsis, acute heart failure, trauma, and respiratory compromise. It is estimated that up to 10% of ED visits may involve patients who experience clinical decline within 48 hours of presentation, with associated in-hospital mortality rates ranging from 6% to 30% depending on the underlying etiology. The healthcare burden includes increased length of stay, resource utilization, and long-term sequelae, underscoring the need for robust early warning systems. Biomarkers capable of predicting deterioration could significantly impact triage accuracy and resource allocation.

Pathophysiology

Clinical deterioration often results from a complex interplay of cellular injury, inflammation, neurohormonal activation, and organ dysfunction. Biomarkers such as lactate, procalcitonin (PCT), C-reactive protein (CRP), troponins, B-type natriuretic peptide (BNP), and D-dimer reflect different facets of this cascade. For example, lactate indicates tissue hypoperfusion and anaerobic metabolism, PCT and CRP mark systemic inflammatory responses, while BNP is a surrogate for myocardial strain and volume overload. Emerging biomarkers, including presepsin, soluble urokinase-type plasminogen activator receptor (suPAR), and mid-regional pro-adrenomedullin (MR-proADM), are providing new mechanistic insights into immune activation, endothelial dysfunction, and vascular integrity during acute physiological stress.

Risk Factors

Several risk factors predispose patients to early clinical deterioration: advanced age, comorbidities (e.g., chronic heart or lung disease, diabetes), immunosuppression, atypical presentations, high disease severity scores at admission, and delays in initial treatment. Biomarker panels, when combined with clinical risk stratification tools, enhance predictive accuracy by identifying high-risk individuals who may otherwise appear stable. For instance, elevated lactate levels in normotensive sepsis patients portend higher mortality even in the absence of overt shock, highlighting the value of biochemical assessment alongside traditional risk factors.

Clinical Features

Clinical deterioration may manifest as subtle changes in mental status, tachypnea, hypotension, tachycardia, hypoxemia, or oliguria, but these signs are often late indicators of severe underlying pathology. Biomarkers provide an objective, quantifiable means of detecting pathophysiological changes before they translate into obvious clinical signs. For example, rising troponin levels may precede ECG changes in myocardial infarction, while an increasing trend in PCT can signal evolving sepsis before hemodynamic instability develops. Serial measurement and trending of biomarkers thus facilitate dynamic risk assessment and early escalation of care.

Diagnosis

Diagnosis of impending clinical deterioration is multifaceted, relying on integration of clinical assessment, vital signs, imaging, and laboratory tests. Biomarkers such as lactate (>2 mmol/L), PCT (>0.5 ng/mL), and BNP (>400 pg/mL) have established diagnostic thresholds associated with increased risk of adverse outcomes. Novel assays, including MR-proADM and suPAR, are under investigation for their additive value in early detection. The use of multi-biomarker algorithms and point-of-care testing is expanding, aiming to improve diagnostic precision, particularly in resource-limited or high-acuity environments.

Treatment & Management

Timely identification of high-risk patients using biomarkers enables rapid initiation of goal-directed therapies, such as early antibiotics in sepsis, vasopressors for shock, or non-invasive ventilation for acute respiratory failure. Biomarker-guided protocols have demonstrated benefits in reducing time to intervention, optimizing fluid resuscitation, and minimizing unnecessary admissions. For instance, lactate clearance is now a key target in sepsis bundles, while BNP levels can guide diuretic therapy in acute heart failure. Close monitoring of biomarker trends supports ongoing clinical decision-making and disposition planning.

Recent Advances / Emerging Therapies

Recent advances include the development of highly sensitive assays, integration with electronic clinical decision support systems, and the emergence of new biomarkers reflecting novel pathophysiological pathways. Presepsin and MR-proADM have shown promise in differentiating bacterial from viral infections and predicting septic shock, respectively. The combination of biomarkers with machine learning algorithms is being explored to enhance predictive accuracy and personalize care. Additionally, advances in point-of-care technology are facilitating rapid bedside testing, shortening turnaround times and enabling real-time risk stratification.

Guideline Recommendations

International guidelines, including those from the Surviving Sepsis Campaign and the American College of Emergency Physicians, endorse the use of biomarkers such as lactate and PCT for risk assessment and monitoring response to therapy in critically ill patients. However, they emphasize that biomarker data should complement, not replace, clinical judgment and comprehensive patient evaluation. Regular updates of guidelines reflect the evolving evidence base and encourage the integration of new biomarkers as validation studies mature.

Conclusion

Emergency biomarkers represent a pivotal tool in the early identification and management of clinical deterioration, offering mechanistic insights and enhancing risk stratification beyond traditional clinical parameters. While established markers such as lactate, PCT, and BNP are now embedded in acute care algorithms, ongoing research into novel biomarkers and multi-marker strategies promises to further refine early warning systems. The integration of biomarker data with clinical acumen and emerging technologies holds the potential to transform acute care, improve patient outcomes, and optimize resource utilization.